KYNTRA BIO, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
KYNTRA BIO, INC. (KYNB) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $47.39 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2018-11-08
- KYNTRA BIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2018-09-30 was $22.00M, a 120.00% increase year-over-year.
- KYNTRA BIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2018-06-30 was $8.21M, a 17.78% decline year-over-year.
- KYNTRA BIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2018-03-31 was $17.18M, a 23.92% increase year-over-year.
- KYNTRA BIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2017-12-31 was $23.57M.
- KYNTRA BIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2017 was $57.42M, a 355.11% increase from fiscal 2016.
- KYNTRA BIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2016 was $12.62M, a 43.93% decline from fiscal 2015.
- KYNTRA BIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2015 was $22.50M, a 50.60% decline from fiscal 2014.
- KYNTRA BIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2014 was $45.55M, a 4454.60% increase from fiscal 2013.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2018-09-30 | $22.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $30.21M derived: sum of 2 quarters · filed 2018-11-08 | $47.39M 10-Q · filed 2018-11-08 | $70.96M derived: sum of 4 quarters · filed 2018-11-08 |
| 2018-06-30 | $8.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $25.39M 10-Q · filed 2018-08-07 | $48.96M derived: sum of 3 quarters · filed 2018-08-07 | $58.96M derived: sum of 4 quarters · filed 2018-11-08 |
| 2018-03-31 | $17.18M 10-Q · filed 2018-05-09 | $40.75M derived: sum of 2 quarters · filed 2018-05-09 | $50.75M derived: sum of 3 quarters · filed 2018-11-08 | $60.74M derived: sum of 4 quarters · filed 2018-11-08 |
| 2017-12-31 | $23.57M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $33.57M derived: sum of 2 quarters · filed 2018-11-08 | $43.56M derived: sum of 3 quarters · filed 2018-11-08 | $57.42M 10-K · filed 2018-02-27 |
| 2017-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $19.98M derived: sum of 2 quarters · filed 2018-11-08 | $33.85M 10-Q · filed 2018-11-08 | $33.85M derived: sum of 4 quarters · filed 2018-11-08 |
| 2017-06-30 | $9.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $23.85M 10-Q · filed 2018-08-07 | $23.85M derived: sum of 3 quarters · filed 2018-08-07 | $28.25M derived: sum of 4 quarters · filed 2018-08-07 |
| 2017-03-31 | $13.86M 10-Q · filed 2018-05-09 | $13.86M derived: sum of 2 quarters · filed 2018-05-09 | $18.26M derived: sum of 3 quarters · filed 2018-05-09 | $20.50M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $4.40M derived: sum of 2 quarters · filed 2018-02-27 | $6.64M derived: sum of 3 quarters · filed 2018-02-27 | $12.62M 10-K · filed 2018-02-27 |
| 2016-09-30 | $4.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $6.64M derived: sum of 2 quarters · filed 2017-11-08 | $12.62M 10-Q · filed 2017-11-08 | $21.08M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $2.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $8.22M 10-Q · filed 2017-08-07 | $16.68M derived: sum of 3 quarters · filed 2018-02-27 | $23.68M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $5.98M 10-Q · filed 2017-05-09 | $14.44M derived: sum of 2 quarters · filed 2018-02-27 | $21.44M derived: sum of 3 quarters · filed 2018-02-27 | $23.48M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $8.47M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $15.47M derived: sum of 2 quarters · filed 2018-02-27 | $17.50M derived: sum of 3 quarters · filed 2018-02-27 | $22.50M 10-K · filed 2018-02-27 |
| 2015-09-30 | $7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | $9.04M derived: sum of 2 quarters · filed 2016-11-08 | $14.04M 10-Q · filed 2016-11-08 | $21.04M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $7.04M 10-Q · filed 2016-08-08 | $14.04M derived: sum of 3 quarters · filed 2017-03-01 | $19.04M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $5.00M 10-Q · filed 2016-05-09 | $12.00M derived: sum of 2 quarters · filed 2017-03-01 | $17.00M derived: sum of 3 quarters · filed 2017-03-01 | $36.00M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $12.00M derived: sum of 2 quarters · filed 2017-03-01 | $31.00M derived: sum of 3 quarters · filed 2017-03-01 | $45.55M 10-K · filed 2017-03-01 |
| 2014-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $24.00M derived: sum of 2 quarters · filed 2015-11-12 | $38.55M 10-Q · filed 2015-11-12 | |
| 2014-06-30 | $19.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $33.55M 10-Q · filed 2015-08-13 | ||
| 2014-03-31 | $14.55M 10-Q · filed 2015-05-12 | |||
| 2013-12-31 | $1.00M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |